Infliximab
Indication
First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Red
Brand:
Remicade® Inflectra® Remsima®
Nice TA:
329
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
Infliximab is also recommended as a possible treatment for children or young people aged 6–17 years with severe ulcerative colitis, if conventional therapy hasn’t worked or isn’t suitable. (When used by children’s services NHS England is the responsible commissioner)
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: